Cargando…

Quantitative pharmacology in antibody-drug conjugate development: armed antibodies or targeted small molecules?

Detalles Bibliográficos
Autores principales:	Nessler, Ian, Khera, Eshita, Thurber, Greg M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2018
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6049322/ https://www.ncbi.nlm.nih.gov/pubmed/30035177 http://dx.doi.org/10.18632/oncoscience.435

Ejemplares similares

Design of high avidity and low affinity antibodies for in situ control of antibody drug conjugate targeting
por: Evans, Reginald, et al.
Publicado: (2022)

Co-administered antibody improves penetration of antibody–dye conjugate into human cancers with implications for antibody–drug conjugates
por: Lu, Guolan, et al.
Publicado: (2020)

Conjugates of Small Molecule Drugs with Antibodies and Other Proteins
por: Feng, Yang, et al.
Publicado: (2014)

Clinical Pharmacology of Antibody-Drug Conjugates
por: Mahmood, Iftekhar
Publicado: (2021)

Tracking Antibody Distribution with Near-Infrared Fluorescent Dyes: Impact of Dye Structure and Degree of Labeling on Plasma Clearance
por: Cilliers, Cornelius, et al.
Publicado: (2017)

Factors Affecting the Pharmacology of Antibody–Drug Conjugates
por: Lucas, Andrew T., et al.
Publicado: (2018)

Antibody–Drug Conjugate Sacituzumab Govitecan Drives Efficient Tissue Penetration and Rapid Intracellular Drug Release
por: Kopp, Anna, et al.
Publicado: (2023)

Pharmacologic Considerations in the Disposition of Antibodies and Antibody-Drug Conjugates in Preclinical Models and in Patients
por: Lucas, Andrew T., et al.
Publicado: (2019)

Reaching Un-Drugable Intracellular Targets with the Long Arm of Antibodies
por: Scheinberg, David A., et al.
Publicado: (2013)

Generation of DAR1 Antibody-Drug Conjugates for Ultrapotent Payloads Using Tailored GlycoConnect Technology
por: de Bever, Laureen, et al.
Publicado: (2023)

Development of and insights from systems pharmacology models of antibody‐drug conjugates
por: Lam, Inez, et al.
Publicado: (2022)

Targeting and pharmacology of an anti-IL13Rα2 antibody and antibody-drug conjugate in a melanoma xenograft model
por: Gupta, Parul, et al.
Publicado: (2021)

Decoupling stability and release in disulfide bonds with antibody-small molecule conjugates
por: Pillow, Thomas H., et al.
Publicado: (2017)

Antibody-Oligonucleotide Conjugates: A Twist to Antibody-Drug Conjugates
por: Dugal-Tessier, Julien, et al.
Publicado: (2021)

Quantifying ADC bystander payload penetration with cellular resolution using pharmacodynamic mapping
por: Khera, Eshita, et al.
Publicado: (2020)

Clinical pharmacology strategies in supporting drug development and approval of antibody–drug conjugates in oncology
por: Liu, Stephanie N., et al.
Publicado: (2021)

Tools to compare antibody gold nanoparticle conjugates for a small molecule immunoassay
por: Conrad, Monika, et al.
Publicado: (2023)

Antibody-Drug Conjugate Targeting c-Kit for the Treatment of Small Cell Lung Cancer
por: Kim, Kwang-Hyeok, et al.
Publicado: (2022)

Targeting cancer with antibody-drug conjugates: Promises and challenges
por: Dean, Alexis Q., et al.
Publicado: (2021)

Practical Guide for Quantification of In Vivo Degradation Rates for Therapeutic Proteins with Single-Cell Resolution Using Fluorescence Ratio Imaging
por: Nessler, Ian, et al.
Publicado: (2020)

Antigen-armed antibodies against B-cell malignancies
por: Ilecka, Marta, et al.
Publicado: (2018)

Introduction to Antibody-Drug Conjugates
por: Pettinato, Mark C.
Publicado: (2021)

ANTIBODY DRUG CONJUGATES (ADCS)
por: Terpos, E.
Publicado: (2023)

A bifunctional molecule-based strategy for the development of theranostic antibody-drug conjugate
por: Xiao, Dian, et al.
Publicado: (2021)

Monoclonal Antibodies and Antibody Drug Conjugates in Multiple Myeloma
por: Radocha, Jakub, et al.
Publicado: (2021)

A CD205-directed antibody drug conjugate – lymphoma precision oncology or sophisticated chemotherapy?
por: Rieke, Damian T., et al.
Publicado: (2020)

Computational selection of antibody-drug conjugate targets for breast cancer
por: Fauteux, François, et al.
Publicado: (2015)

Antibody drug conjugate: the “biological missile” for targeted cancer therapy
por: Fu, Zhiwen, et al.
Publicado: (2022)

Antibody-drug conjugates: the paradigm shifts in the targeted cancer therapy
por: Aggarwal, Devesh, et al.
Publicado: (2023)

Antibody-conjugated nanoparticles for target-specific drug delivery of chemotherapeutics
por: Kumari, Mamta, et al.
Publicado: (2023)

Advances in Targeted Therapy of Breast Cancer with Antibody-Drug Conjugate
por: Subhan, Md Abdus, et al.
Publicado: (2023)

Oral and Subcutaneous Administration of a Near-Infrared Fluorescent Molecular Imaging Agent Detects Inflammation in a Mouse Model of Rheumatoid Arthritis
por: Bhatnagar, Sumit, et al.
Publicado: (2019)

Antibody-Drug Conjugates in Bladder Cancer
por: Vlachostergios, Panagiotis J., et al.
Publicado: (2018)

Antibody-Drug Conjugates: Possibilities and Challenges
por: Nejadmoghaddam, Mohammad-Reza, et al.
Publicado: (2019)

Acquired Resistance to Antibody-Drug Conjugates
por: Collins, Denis M., et al.
Publicado: (2019)

Antibody–Drug Conjugates for Cancer Therapy
por: Parslow, Adam C., et al.
Publicado: (2016)

Antibody–Drug Conjugates: The Last Decade
por: Joubert, Nicolas, et al.
Publicado: (2020)

Antibody–Drug Conjugates for Cancer Therapy
por: Hafeez, Umbreen, et al.
Publicado: (2020)

Antibody-drug conjugates: Present and future
por: Beck, Alain, et al.
Publicado: (2013)

Antibody–Drug Conjugate to Treat Meningiomas
por: Chen, Kai, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_rhh2tapbaov5m13ougn224plfb